

2018

Metabolic obesity phenotypes and risk of colorectal cancer in postmenopausal women.

G. C. Kabat

M. Y. Kim

M. Stefanick

G. Y. F. Ho

Zucker School of Medicine at Hofstra/Northwell, gho1@northwell.edu

D. S. Lane

See next page for additional authors

Follow this and additional works at: <https://academicworks.medicine.hofstra.edu/articles>



Part of the [Epidemiology Commons](#)

Recommended Citation

Kabat GC, Kim MY, Stefanick M, Ho GY, Lane DS, Odegaard AO, Simon MS, Bea JW, Luo J, Wassertheil-Smoller TE. Metabolic obesity phenotypes and risk of colorectal cancer in postmenopausal women. . 2018 Jan 01; 143(3):Article 6922 [551 p.]. Available from: <https://academicworks.medicine.hofstra.edu/articles/6922>. Free full text article.

This Article is brought to you for free and open access by Donald and Barbara Zucker School of Medicine Academic Works. It has been accepted for inclusion in Journal Articles by an authorized administrator of Donald and Barbara Zucker School of Medicine Academic Works. For more information, please contact academicworks@hofstra.edu.

Authors

G. C. Kabat, M. Y. Kim, M. Stefanick, G. Y. F. Ho, D. S. Lane, A. O. Odegaard, M. S. Simon, J. W. Bea, J. Luo, and T. E. Wassertheil-Smoller



HHS Public Access

Author manuscript

Int J Cancer. Author manuscript; available in PMC 2019 November 25.

Published in final edited form as:

Int J Cancer. 2018 August 01; 143(3): 543–551. doi:10.1002/ijc.31345.

Metabolic obesity phenotypes and risk of colorectal cancer in postmenopausal women

Geoffrey C. Kabat¹, Mimi Y. Kim¹, Marcia Stefanick², Gloria Y.F. Ho³, Dorothy S. Lane⁴, Andrew O. Odegaard⁵, Michael S. Simon⁶, Jennifer W. Bea⁷, Juhua Luo⁸, Sylvia Wassertheil-Smoller¹, Thomas E. Rohan¹

¹Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY

²Department of Medicine, Stanford University, Stanford, CA

³Department of Occupational Medicine, Epidemiology and Prevention, Northwell Health, Great Neck, NY

⁴Department of Preventive Medicine, School of Medicine, Stony Brook University, Stony Brook, NY

⁵Department of Epidemiology, School of Medicine, University of California at Irvine, Irvine, CA

⁶Karmanos Cancer Institute, Detroit, MI

⁷Department of Medicine, Arizona Cancer Center, Tucson, AZ

⁸Department of Epidemiology and Biostatistics, School of Public Health, University of Indiana, Bloomington, IN

Abstract

Obesity has been postulated to increase the risk of colorectal cancer by mechanisms involving insulin resistance and the metabolic syndrome. We examined the associations of body mass index (BMI), waist circumference, the metabolic syndrome, metabolic obesity phenotypes and homeostasis model-insulin resistance (HOMA-IR—a marker of insulin resistance) with risk of

Correspondence to: Geoffrey C. Kabat, Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY 10461, USA, Tel.: +1-718-430-3038, Fax: + 1718-430-2000, geoffrey.kabat@einstein.yu.edu.

Additional Contributions: The authors thank the Women's Health Initiative investigators, staff and the trial participants for their outstanding dedication and commitment.

Women's Health Initiative Investigators:

Program office: Jacques Roscoe, Shari Ludlum, Dale Burden, Joan McGowan, Leslie Ford and Nancy Geller (National Heart, Lung, and Blood Institute, Bethesda, MD)

Clinical coordinating center: Garnet Anderson, Ross Prentice, Andrea LaCroix and Charles Kopperberg (Fred Hutchinson Cancer Research Center, Seattle, WA)

Investigators and academic centers: JoAnn E. Manson, Brigham and Women's Hospital, Harvard Medical School, Boston, MA; Barbara V. Howard, MedStar Health Research Institute/Howard University, Washington, DC; Marcia L. Stefanick, Stanford Prevention Research Center, Stanford, CA; Rebecca Jackson, The Ohio State University, Columbus, OH; Cynthia A. Thompson, University of Arizona, Tucson/Phoenix, AZ; Jean Wactawski-Wende, University at Buffalo, Buffalo, NY; Marian Limacher, University of Florida, Gainesville/Jacksonville, FL; Robert Wallace, University of Iowa, Iowa City/Davenport, IA; Lewis Kuller, University of Pittsburgh, Pittsburgh, PA; Rowan T. Chlebowski, City of Hope Comprehensive Cancer Center, Duarte, CA; Sally Shumaker, Wake Forest University School of Medicine, Winston-Salem, NC

Women's Health Initiative Memory Study: (Wake Forest University School of Medicine, Winston Salem, NC) Sally Shumaker

Additional information: A full list of all the investigators who have contributed to Women's Health Initiative science appears at <https://www.whi.org/researchers/Documents%20%20Write%20a%20Paper/WHI%20Investigator%20Long%20List.pdf>

colorectal cancer in over 21,000 women in the Women's Health Initiative CVD Biomarkers subcohort. Women were cross-classified by BMI (18.5–<25.0, 25.0–<30.0 and ≥ 30.0 kg/m²) and presence of the metabolic syndrome into 6 phenotypes: metabolically healthy normal weight (MHNW), metabolically unhealthy normal weight (MUNW), metabolically healthy overweight (MHOW), metabolically unhealthy overweight (MUOW), metabolically healthy obese (MHO) and metabolically unhealthy obese (MUO). Neither BMI nor presence of the metabolic syndrome was associated with risk of colorectal cancer, whereas waist circumference showed a robust positive association. Relative to the MHNW phenotype, the MUNW phenotype was associated with increased risk, whereas no other phenotype showed an association. Furthermore, HOMA-IR was not associated with increased risk. Overall, our results do not support a direct role of metabolic dysregulation in the development of colorectal cancer; however, they do suggest that higher waist circumference is a risk factor, possibly reflecting the effects of increased levels of cytokines and hormones in visceral abdominal fat on colorectal carcinogenesis.

Keywords

body mass index; waist circumference; metabolic status; HOMA-IR; colorectal cancer risk; postmenopausal women

Obesity is associated with increased risk of colorectal cancer.^{1–6} Both higher levels of body mass index (BMI, kg/m²) and other measures of adiposity, such as waist circumference, are risk factors for the disease,^{1–6} although both obesity measures show weaker associations in women compared to men.^{5,6} Insulin resistance and hyperinsulinemia are frequently present in obese individuals and have been posited to play a role in colorectal cancer.⁷ In this regard, relatively high circulating insulin and glucose levels have been associated with increased colorectal cancer risk.^{8–10} Insulin resistance is one component of the metabolic syndrome, which includes hyperlipidemia and hypertension as well.¹¹ In an analysis conducted in a subcohort of the Women's Health Initiative,¹² presence of the metabolic syndrome was associated with increased risk of colorectal cancer in postmenopausal women (HR 2.15, 95% CI 1.30–3.53) and colon cancer (HR 2.28, 95% CI 1.31–3.98). A meta-analysis¹³ reported that presence of the metabolic syndrome was associated with increased risk colorectal cancer in both men and women.

To date, few studies have examined the association of metabolically defined body size phenotypes with risk of colorectal cancer.^{14,15} In a nested case–control study within the European Prospective Investigation into Cancer and Nutrition (EPIC),¹⁴ compared to normal weight individuals without hyperinsulinemia (indicated by C-peptide level), both normal weight individuals (BMI < 25 kg/m²) and overweight individuals (BMI ≥ 25.0 kg/m²) with hyperinsulinemia were at increased risk of colorectal cancer. In contrast, among those without hyperinsulinemia, overweight individuals were not at increased risk compared to normal weight individuals. Generally similar results were seen when waist circumference was used to assess adiposity instead of BMI. In an analysis restricted to normal weight women in the Women's Health Initiative,¹⁵ metabolically unhealthy normal weight women were at increased risk of colorectal cancer compared to metabolically healthy normal weight women.

Here we examine the association of 6 obesity phenotypes, defined at baseline by combinations of body weight and metabolic health, as well as homeostasis model assessment-insulin resistance (HOMA-IR), a marker of insulin resistance, with risk of colorectal cancer in the CVD biomarkers cohort of 24,210 participants in the Women's Health Initiative study.

Methods

The Women's Health Initiative is a large, multicenter study designed to improve our understanding of the determinants of major chronic diseases in postmenopausal women. It is composed of a clinical trial component (CT, $n = 68,132$) and an observational study component (OS, $n = 93,676$).¹⁶ The CT component included four randomized controlled intervention studies: hormone therapy (two trials), low-fat dietary modification and calcium + vitamin D supplementation. Women between the ages of 50 and 79 and representing the major racial/ethnic groups were recruited from the general population at 40 clinical centers throughout the US between 1993 and 1998. Details of the study design and reliability of the baseline measures have been published.^{16,17}

The CVD biomarkers subsample

Individuals who had baseline measurements of fasting serum glucose and insulin and other clinical parameters that were made in various sub-studies within WHI were assembled into the CVD biomarkers subsample ($n = 25,446$). Some sub-studies entailed selecting a random sample; others selected participants based on specific age and ethnicity/race criteria within the hormone therapy trials; another sub-study was a nested case-control study within the hormone therapy trials with random sampling of controls (Fig. 1).

Follow-up and ascertainment of outcomes

Clinical outcomes (including new cancer diagnoses) were updated semiannually in the CT and annually in the OS using in-person, mailed or telephone questionnaires. Self-reports of malignancy were verified by central review of medical records and pathology reports by trained physician adjudicators.¹⁸

Covariates

At study entry, self-administered questionnaires were used to collect information on demographics, medical and reproductive history, family history of cancer, and lifestyle factors, including smoking history, alcohol consumption, dietary habits, and recreational physical activity. All participants had their weight, height, waist and hip circumference measured by trained staff at baseline. Weight was measured to the nearest 0.1 kg, and height to the nearest 0.1 cm. Waist circumference was measured with a tape measure at the narrowest part of the torso between the participant's ribs and iliac crest. Hip circumference was measured at the site of maximum extension of the buttocks. BMI was computed as weight in kilograms divided by the square of height in meters. Two blood pressure measurements were obtained 30 sec apart, and the average of the 2 measurements was used in the analysis. Questions about physical activity at baseline referred to a woman's usual pattern of activity, including walking and recreational physical activity. A variable "current

total leisure-time physical activity” (MET-hr/week) was computed by multiplying the number of hours per week of leisure-time physical activity by the metabolic equivalent (MET) value of the activity and summing over all types of activities.¹⁹

Assays for glucose, HDL-C and triglycerides

Blood was obtained after at least 8 hr of fasting for 99.8% of participants in the subsample. The specimens were centrifuged, and serum and plasma were frozen at -70°C and shipped on dry ice to a central processing facility, where they were stored at -80°C . HDL-C was measured in serum using the HDLC Plus 3rd Generation Direct Method (Roche) on the Roche Modular P Chemistry Analyzer. Triglycerides were measured in serum using Triglyceride GB reagent (Roche) on the Roche Modular P Chemistry Analyzer. In the vast majority of women ($n = 22,314$, 88%), glucose was measured in serum using the Glucoquant Glucose/hexokinase reagent (Roche Diagnostics, Indianapolis, IN 46250) on the Roche Modular P Chemistry analyzer (Roche Diagnostics Corporation); in the remainder, serum glucose was determined by the hexokinase method on the Hitachi 747 (Boehringer Mannheim Diagnostics, Indianapolis, IN). Insulin was determined using the Sandwich Immunoassay (Roche Diagnostics) on Roche Elecsys 2010 Analyzer.

Definition of the metabolic syndrome

We used the National Cholesterol Education Program (NCEP) Adult Treatment Panel III (ATP III) definition of the metabolic syndrome: having 3 of the 5 following criteria: waist circumference ≥ 88 cm, triglycerides ≥ 150 mg/dl, HDL-C <50 mg/dl, glucose ≥ 100 mg/dl and systolic/diastolic blood pressure $\geq 130/85$ mmHg or treatment for hypertension.¹¹ To assess the relative contributions of adiposity and metabolic factors to the risk of colorectal cancer, we also examined the metabolic obesity phenotypes using an alternative definition which excluded waist circumference from the ATP III definition (presence of the metabolic syndrome defined as 2 of the 4 remaining components). Furthermore, because the metabolic syndrome is a constellation of heterogeneous factors, we additionally computed homeostasis model assessment-insulin resistance (HOMA-IR), a measure of insulin resistance, using the formula (fasting glucose (mg/dl) \times fasting insulin (mg/dl)/405).²⁰

Exclusions

For the purposes of the present analysis, baseline BMI and components of the metabolic syndrome were available for 23,900 (99%) of the 24,210 women in the subsample. We excluded women with diabetes reported at baseline ($n = 2,346$, 9.7%), women with BMI <18.5 ($n = 310$, 1.3%), women missing waist circumference measurements ($n = 59$, 0.2%) and women with a history of colorectal cancer ($n = 387$, 1.6%). Women with diabetes reported at enrollment were excluded for two reasons: (i) our focus is on the influence of the metabolic syndrome, which is a precursor of diabetes and (ii) treatment of diabetes may influence the clinical factors (i.e., components of the metabolic syndrome). After exclusions (some of which were overlapping), 21,170 women were available for analysis (88% of women with information on the metabolic syndrome and BMI), among whom, as of September 30, 2016, 474 incident invasive colorectal cancer cases had been ascertained. Of these, 397 were classified as colon cancer, 47 as rectal cancer and 5 as both colon and rectal cancer. For 25 cases, information on subsite was not available. We compared the distribution

of sociodemographic and lifestyle variables in excluded women to the distribution in the study population. Most factors, including age, BMI, WC, smoking, caloric intake, education and hormone therapy did not differ between excluded and included subjects. However, alcohol intake, physical activity and the proportion of whites were lower in the excluded subjects.

Statistical analysis

Cox proportional hazards models were used to estimate hazard ratios (HRs) and 95% confidence intervals (CI) for the associations of interest. The outcome was time to diagnosis of colorectal cancer. Participants who had not developed the disease by the end of follow-up, who had died or who withdrew from the study before the end of follow-up were censored. Cases contributed person-time to the study from their date of enrollment until the date of diagnosis, and noncases (participants who were censored) contributed person-time from their date of enrollment until the date of withdrawal from the study, the date of death, or the end of follow-up (September 30, 2016), whichever came first. We examined both age-adjusted and fully-adjusted models, which included colorectal cancer risk factors as well as other potential confounding variables. As the results differed little, we present the fully adjusted results. We also adjusted for red meat intake; however, this made no difference, and meat was not included in the final model.

We examined the association of categories of BMI (18.5– <25.0, normal weight; 25.0– <30.0, overweight; ≥ 30.0 kg/m², obese) and waist circumference (<83.0, 83.0–<95.0 and ≥ 95.0 cm) and of presence of the metabolic syndrome, separately and with mutual adjustment, with risk of colorectal cancer. We then estimated risk after cross-classifying women by categories of BMI and presence of the metabolic syndrome simultaneously, yielding six groups: metabolically healthy/normal weight (MHNW); metabolically unhealthy/normal weight (MUNW); metabolically healthy/overweight (MHOW); metabolically unhealthy/overweight (MUOW); metabolically healthy/obese (MHO); metabolically unhealthy/obese (MUO).

Because the metabolic syndrome is a composite, which additionally includes components other than those related to hyperglycemia/hyperinsulinemia (i.e., lipids and hypertension), we also examined the associations of other components of the metabolic syndrome (hypertension, HDL-C and triglycerides) and quartiles of HOMA-IR with risk of colorectal cancer, with and without adjustment for BMI and waist circumference.

Tests for linear trend were performed by assigning the median value to each category, modeling the variable as a continuous variable, and using the Wald test for linear trend ($p < 0.05$).

We conducted four sensitivity analyses: (i) we excluded the first 3 years of follow-up to address the possibility of reverse causation (effects of subclinical cancer on body weight and metabolic status). (ii) Because waist circumference is strongly correlated with BMI, we repeated the analyses after excluding waist circumference from the definition of the metabolic syndrome and defining presence of the syndrome as ≥ 2 of the four remaining components. (iii) Because participation in the intervention arm of the dietary clinical trials

could affect the results, we repeated the main analyses excluding women who were in these interventions. (iv) Because the distribution of clinical variables (including glucose and insulin) differed in the 4 studies making up the subcohort, as an alternative to using cut-points derived from the total study population, we reanalyzed the data for the association of glucose, HLD-C, triglycerides and HOMA-IR, with colorectal cancer using the original cut-points from each study and “stacking” the different studies.

We tested the proportional hazards assumption using PROC LIFETEST (SAS Institute, Cary, NC). Formal tests for nonproportional hazards and the log–log survival plots did not indicate any marked deviation from the proportional hazards assumption. All analyses were performed in SAS 9.4 (SAS Institute, Cary, NC). All *p* values are two-sided.

Results

The metabolic obesity phenotypes showed differences by demographic and behavioral characteristics (Table 1). Within BMI categories, compared to metabolically healthy women, metabolically unhealthy women tended to be older and to have fewer years of education, and were more likely to be white and to be current smokers. Both alcohol intake and MET-hr/week of physical activity showed decreasing trends from MHNW to MUO.

Neither body mass index nor presence of the metabolic syndrome was associated with colorectal cancer risk—in age-adjusted models, when considered separately with adjustment for other covariates, or when mutually adjusted (Table 2). The results were similar in women who had never used hormone therapy (data not shown).

In the age-adjusted model and the model adjusted for covariates other than the metabolic syndrome, waist circumference was positively associated with colorectal cancer risk (HR for highest tertile 1.34, 95% CI 1.04–1.72), whereas the metabolic syndrome was not associated with altered risk (Table 3). When waist circumference and presence of the metabolic syndrome were mutually adjusted, the HR for waist circumference was slightly attenuated, and that for the metabolic syndrome was further weakened. Similar results were seen when the analysis was restricted to never users of hormone therapy (data not shown).

When waist circumference and BMI were entered in the same model with metabolic syndrome, HRs for the 2nd and 3rd tertile of waist circumference were 1.40, 95% CI 1.031–1.89 and 2.29, 95% CI 1.57–3.35, respectively, *p* for trend <0.0001, and HRs for BMI 25.0–30.0 and for BMI ≥30.0 kg/m² were 0.69, 95% CI 0.51–0.93 and 0.48, 95% CI 0.33–0.70, respectively, *p* for trend = 0.01. Presence of the metabolic syndrome continued to show no association (data not shown).

Compared to metabolically healthy normal weight women (reference group), only metabolically unhealthy normal weight women had an elevated HR (1.65, 95% CI 0.99–2.74) (Table 4). No other group showed any suggestion of an elevated risk (in spite of the larger numbers compared to the MUNW group). When the first 3 years of follow-up were excluded to address the possibility of reverse causation, the results were similar, although the confidence intervals were wider due to the decreased sample size. When examined individually, with the exception of waist circumference, none of the components of the

metabolic syndrome (glucose, HDL-C, triglycerides or hypertension) showed any association with colorectal cancer (data not shown). In the sensitivity analysis excluding women in the intervention arms of the 2 dietary clinical trials, the association of BMI and WC with CRC were unchanged, whereas the association of MUNW with CRC was strengthened (HR 1.83, 95% CI 1.04–3.21).

HOMA-IR, a measure of insulin resistance, showed no association with colorectal cancer; however, in the same model, waist circumference showed a robust positive association (Table 5). The pattern of associations was unchanged when the analysis was restricted to women who had never used hormone therapy (data not shown).

In the analyses restricted to colon cancer, the HR for presence of the metabolic syndrome was 1.22, 95% CI 0.98–1.52 and the HRs for colon cancer associated with the different phenotypes, relative to the MHNW phenotype, were MUNW 1.79, 95% CI 1.02–3.12; MHOW 0.87, 95% CI 0.63–1.21; MUOW 1.26, 95% CI 0.87–1.83; MHO 0.93, 95% CI 0.64–1.36; MUO 1.12, 95% CI 0.80–1.56. The association of waist circumference with colon cancer was strengthened (HR for highest vs. lowest tertile 1.45, 95% CI 1.10–1.91).

In the sensitivity analysis in which waist circumference was not included as a component of the metabolic syndrome, the HR for MUNW relative to MHNW was attenuated (1.35, 95% CI 0.91–2.02). None of the other metabolic phenotypes was associated with risk (Supporting Information, Table). In the sensitivity analysis using the original study-specific cutpoints, the results were unchanged.

Discussion

In this prospective study of postmenopausal women, BMI was not associated with risk of colorectal cancer, whereas waist circumference was positively associated with risk. Of 5 metabolic obesity phenotypes, relative to metabolically healthy normal weight women, only metabolically unhealthy normal weight women showed a borderline increased risk. Individual components of the metabolic syndrome showed no association. Furthermore, HOMA-IR was not associated with risk. Overall, our results suggest that that abdominal adiposity is a robust risk factor for colorectal cancer in women, whereas both presence of the metabolic syndrome and insulin resistance showed no overall association and only a possible association in normal weight women.

Two previous studies suggest that metabolically unhealthy normal weight individuals are at elevated risk of colorectal cancer compared to metabolically healthy normal weight individuals,^{14,15} and one of these¹⁴ indicated that metabolically unhealthy overweight individuals were at increased risk compared to metabolically healthy normal weight and to metabolically healthy overweight individuals. Metabolically healthy overweight individuals were not at increased risk compared to metabolically healthy normal weight individuals.¹⁴

In contrast to the EPIC study,¹⁴ our analysis was not limited by comparing normal weight *versus* overweight/obese, but included 3 levels of BMI: normal weight, overweight and obese, thereby permitting us to examine the full range of adiposity. Our results are consistent with those of Murphy *et al.*¹⁴ regarding MUNW *versus* MHNW; however, we found little

indication that either the MUOW or MUO phenotypes were at increased risk relative to MHNW women.

Differences between our results and those of Liang *et al.*,¹⁵ which also made use of the CVD biomarkers subcohort of the Women's Health Initiative, can be explained by the different analytic approaches taken in the two analyses. Liang *et al.* restricted attention to normal weight women in WHI, whereas we included normal weight, overweight and obese women. Further, Liang *et al.* excluded women with a history of any cancer (except nonmelanoma skin cancer), whereas we only excluded women with a history of colorectal cancer. On the other hand, we excluded women with a history of diabetes, whereas Liang *et al.* did not. The number of cases among normal weight women in the two analyses were 114 (Liang *et al.*) and 134 (this study). Our approach permitted us to examine waist circumference, BMI and HOMA-IR in the total study population (474 cases and 20,696 noncases). Thus, our finding of a positive association of waist circumference with risk is not in conflict with Liang *et al.*'s finding of no association of waist circumference with risk in normal weight women. As the number of cases among normal weight women is not large ($n = 114$), it is possible that differences in the selection of subjects and covariates included in the multivariable analyses in the two analyses may account for differences in which factors showed significant associations. For example, Liang *et al.* reported a positive association of fasting glucose (no/yes) with colorectal cancer: HR 1.70, 95% CI 1.12–2.58. The corresponding HR in our study was 1.48, 95% CI 0.92–2.37). Liang *et al.* found no association of waist circumference with risk. In our analysis of normal weight women, tertiles of waist circumference were also not significantly associated with risk, due it appears to the limited sample size: 1.25, 95% CI 0.73–2.15 and 2.86, 95% CI 0.69–11.83, for the second and third tertile, respectively. When treated as a dichotomous variable (<88 cm, ≥88 cm), waist circumference was also not significant (HR 1.18, 95% CI 0.48–2.91). Our results were not altered when women with a history of cancer were excluded from the analysis. Finally, the association of waist circumference with colorectal cancer risk we observed in the WHI CVD biomarkers subcohort is consistent with the association observed in the total WHI cohort.^{4,21}

The hypothesis that obesity and related metabolic alterations are associated with risk of colorectal cancer has gained widespread support in recent years.^{22,23} A meta-analysis summarizing the evidence from cohort studies¹³ indicated that the metabolic syndrome was associated with an elevated risk of colorectal cancer both in men (RR 1.33, 95% CI 1.18–1.50) and in women (RR 1.41, 95% CI 1.18–1.70). The risk associated with dysglycemia was similar to that of the full metabolic syndrome, suggesting that elevated glucose may account for the association with the syndrome. And an analysis of the EPIC cohort²⁴ showed that the association of the metabolic syndrome with colon cancer was largely accounted for by abdominal obesity and abnormal glucose metabolism, suggesting that excess fat storage and consequent hyperglycemia and hyperinsulinemia are important factors.

Our findings provide little support for the hypothesis that metabolic dysregulation is directly associated with increased risk of colorectal cancer. Presence of the metabolic syndrome showed only a modest and imprecise association with colorectal cancer, and, except for waist circumference, the individual components of metabolic syndrome were not associated with risk. HOMA-IR was also not associated with risk; and, of the metabolic phenotypes,

only metabolically unhealthy normal weight women were at increased risk compared to metabolically healthy normal weight women. However, in view of the small number of colorectal cancer cases in this category, this association could be due to chance. On the other hand, waist circumference was significantly associated with increased risk. Our results suggest that centrally located adipose tissue may be an important risk factor for colorectal cancer in women. This association could be driven by visceral (or intraabdominal) fat, as visceral fat is metabolically more active than subcutaneous abdominal fat and secretes larger amounts of cytokines and hormones compared to subcutaneous fat.²⁴ However, we did not have a direct measure of different abdominal adipose tissue depots.

Strengths of this study include its large sample size, the central adjudication of all colorectal cancer diagnoses, the availability of fasting blood samples on virtually all participants, measurements of all components of the metabolic syndrome, as well as insulin and HOMA-IR, and anthropometric measures. Additionally, we carried out sensitivity analyses, first, excluding the first 3 years of follow-up to address the possibility of reverse causality, second, excluding waist circumference from the definition of the metabolic syndrome, since waist circumference is strongly correlated with BMI, which is used to define the metabolic obesity phenotypes. An additional sensitivity analysis excluded women in the intervention arms of the dietary clinical trials, which did not affect the results. Limitations include the small numbers of cases in the MUNW phenotype group and the lack of information on change in metabolic phenotype and adiposity over time. Also, misclassification of the study factors would likely attenuate the observed associations, whereas misclassification of covariates, such as physical activity, could weaken the correction for confounding. However, the main finding, regarding waist, was robust and was consistent in different analyses. Finally, the Women's Health Initiative is not a representative sample and, therefore, our results are not generalizable to all postmenopausal women. Nevertheless, analyses within the cohort should have validity.

In conclusion, in this study, waist circumference was positively associated with risk of colorectal cancer, whereas BMI was not. Compared to metabolically healthy normal weight women, only metabolically unhealthy normal weight women had a borderline elevated risk; no other phenotypes showed any indication of increased risk. Overall, presence of the metabolic syndrome showed little association with risk, and HOMA-IR was not associated with risk. Our results provide little support for a direct association of metabolic dysregulation with risk of colorectal cancer. The association of waist circumference with increased risk, may be mediated by the effects of increased production of cytokines and hormones in visceral adipose tissue.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgements

References

1. Larsson SC, Wolk A. Obesity and colon and rectal cancer risk – a meta-analysis of prospective studies. *Am J Clin Nutr* 2007;86:556–65. [PubMed: 17823417]
2. Ning Y, Wang L, Giovannucci EL. A quantitative analysis of body mass index and colorectal cancer: findings from 56 observational studies. *Obes Rev* 2010;11:19–30. [PubMed: 19538439]
3. Renehan AG, Tyson M, Egger M, et al. Body mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. *Lancet* 2008;371:569–78. [PubMed: 18280327]
4. Kabat GC, Xue X, Kamensky V, et al. Risk of breast, endometrial, colorectal, and renal cancers in postmenopausal women in association with a body shape index and other anthropometric measures. *Cancer Causes Control* 2015;26:219–29. [PubMed: 25430815]
5. Pischon T, Lahmann PH, Boeing H, et al. Body size and risk of colon and rectal cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC). *J Natl Cancer Inst* 2006;98:920–31. [PubMed: 16818856]
6. Kyrgiou M, Kalliala I, Markozannes G, et al. Adiposity and cancer at major anatomical sites: umbrella review of the literature. *BMJ*. 2017;356: j477.
7. Giovannucci E. Metabolic syndrome, hyperinsulinemia, and colon cancer: a review. *Am J Clin Nutr* 2007;86:836S–42S.
8. Gunter MJ, Hoover DR, Yu H, et al. Insulin, insulin-like growth factor-1, endogenous estradiol, and risk of colorectal cancer in postmenopausal women. *Cancer Res* 2008;68:329–37. [PubMed: 18172327]
9. Schoen RE, Tangen CM, Kuller LH, et al. Increased blood glucose and insulin, body size, and incident colorectal cancer. *J Natl Cancer Inst* 1999;91:1147–54. [PubMed: 10393723]
10. Kabat GC, Kim MY, Strickler HD, et al. A longitudinal study of serum insulin and glucose levels in relation to colorectal cancer risk among postmenopausal women. *Br J Cancer* 2012;106:227–32. [PubMed: 22127286]
11. Grundy SM, Cleeman JI, Daniels ST, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. *Circulation* 2005;112:2735–52. [PubMed: 16157765]
12. Kabat GC, Kim MY, Peters U, et al. A longitudinal study of the metabolic syndrome and risk of colorectal cancer in postmenopausal women. *Eur J Cancer Prev* 2012;21:326–32. [PubMed: 22044849]
13. Esposito K, Chiodini P, Capuano A, et al. Colorectal cancer association with metabolic syndrome and its components: a systematic review with meta-analysis. *Endocrine* 2013;44:634–47. [PubMed: 23546613]
14. Murphy N, Cross AJ, Abubakar M, et al. A nested case-control study of metabolically defined body size phenotypes and risk of colorectal cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC). *PLoS Med*. 2016; doi:10.1371/journal.pmed.10011988.
15. Liang X, Margolis KL, Hendryx M, et al. Metabolic phenotype and risk of colorectal cancer in normal-weight postmenopausal women. *Cancer Epidemiol Biomarkers Prev* 2017;26:155–61. [PubMed: 28148595]
16. Anderson GL, Manson J, Wallace R, et al. Implementation of the Women’s Health Initiative study design. *Ann Epidemiol* 2003;13:S5–S17. [PubMed: 14575938]
17. Langer RD, White E, Lewis CE, et al. The Women’s Health Initiative Observational Study: baseline characteristics of participants and reliability of baseline measures. *Ann Epidemiol* 2003;13: S107–21. [PubMed: 14575943]
18. Curb JD, McTiernan A, Heckbert SR, et al. Outcomes ascertainment and adjudication methods in the Women’s Health Initiative. *Ann Epidemiol* 2003;13:S122–8. [PubMed: 14575944]

19. McTiernan A, Kooperberg C, White E, et al. Recreational physical activity and the risk of breast cancer in postmenopausal women: the Women's Health Initiative Cohort Study. *JAMA* 2003;290: 1331–6. [PubMed: 12966124]
20. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and β -cell function from fasting plasma glucose and insulin concentrations in man. *Diabetologia* 1985;28:412–9. [PubMed: 3899825]
21. Kabat GC, Xue X, Kamensky V, et al. Erratum to: risk of breast, endometrial, colorectal, and renal cancers in postmenopausal women in association with a body shape index and other anthropometric measures. *Cancer Causes Control* 2017;28:1007–9. [PubMed: 28752192]
22. Aleksandrova K, Nimptsch K, Pischon T. Influence of obesity and related metabolic alterations on colorectal cancer risk. *Curr Nutr Rep* 2013;2: 1–9. [PubMed: 23396857]
23. Yehuda-Shnaidman E, Schwartz B. Mechanisms linking obesity, inflammation and altered metabolism to colon carcinogenesis. *Obes Rev* 2012;13: 1083–95. [PubMed: 22937964]
24. Aleksandrova K, Boeing H, Jenab M, et al. Metabolic syndrome and risks of colon and rectal cancer: the European Prospective Investigation into Cancer and Nutrition. *Cancer Prev Res (Phila)*. 2011;4:1873–83. [PubMed: 21697276]

What's new?

Obesity is associated with increased risk of colorectal cancer, as is a high level of insulin in the bloodstream. To tease out the relationship between body weight, metabolic health, and colorectal cancer risk, these authors examined data on six different body profiles. Neither BMI nor metabolic syndrome appeared to impact colorectal cancer risk. Waist circumference, however, significantly boosted the risk, possibly due to the increased cytokines and hormones present in fat that accumulates around the waist.




Figure 1.
Make-up of WHI CVD biomarker sample.

Table 1.

Baseline characteristics by metabolic obesity phenotypes¹ (n = 21,170)

Characteristic	MHNW N = 4,612	MUNW N = 563	MHOW N = 5,224	MUOW N = 2,456	MHO N = 3,419	MUO N = 4,941
Mean (SD)						
Age	64.8 (7.5)	66.8 (6.6)	63.8 (7.4)	65.5 (6.9)	62.3 (7.2)	63.4 (7.0)
BMI (kg/m ²)	22.7 (1.6)	23.3 (1.4)	27.3 (1.4)	27.9 (1.4)	34.7 (4.9)	35.6 (4.9)
Waist circumference (cm)	75.0 (6.7)	81.0 (10.4)	83.7 (6.7)	90.2 (7.0)	96.5 (11.2)	103.1 (10.4)
Alcohol intake (drinks/week)	2.7 (5.4)	2.4 (5.1)	2.1 (4.8)	2.0 (4.7)	1.5 (4.5)	1.4 (4.7)
Pack-years of smoking	8.6 (16.5)	12.3 (21.3)	7.6 (15.7)	10.9 (19.1)	7.6 (15.5)	9.8 (18.7)
MET (hr/week)	13.9 (15.3)	11.0 (13.0)	11.7 (13.7)	9.2 (11.6)	8.8 (12.3)	7.1 (10.4)
Aspirin intake	0.20 (90.4)	0.26 (0.44)	0.20 (0.40)	0.23 (0.42)	0.16 (0.38)	0.21 (0.41)
Red meat intake (med. serving/day)	0.58 (0.53)	0.62 (0.54)	0.67 (0.62)	0.72 (0.62)	0.84 (0.82)	0.93 (0.83)
Calcium intake (mg/day)	743 (459)	739 (451)	739 (484)	746 (473)	746 (505)	783 (510)
Folate intake (meg/day)	247 (120)	240 (121)	247 (128)	244 (125)	254 (139)	255 (145)
Caloric intake (kcal/day)	1,499 (676)	1,504 (685)	1,569 (796)	1,584 (725)	1,722 (962)	1,775 (948)
Parity	2.5 (1.7)	2.9 (1.7)	2.7 (1.7)	2.9 (1.7)	2.7 (1.8)	2.9 (1.7)
Proportions						
Education (% postgraduate)	29.3	19.9	27.2	19.4	24.6	18.4
Ethnicity (% white)	56.4	65.7	44.8	56.3	32.4	50.1
% current smokers	12.1	16.6	7.4	12.0	6.1	8.5
Oral contraceptives (% ever used)	37.0	32.8	38.1	34.3	38.2	37.4
Hormone therapy (% ever used)	43.5	40.3	43.3	39.8	40.7	35.1
Family history of colorectal cancer (% yes)	15.5	15.2	15.4	16.4	16.7	16.1

Abbreviations: MHNW, metabolically healthy normal weight; MUNW, metabolically unhealthy normal weight; MHOW, metabolically healthy overweight; MUOW, metabolically unhealthy overweight; MHO, metabolically healthy obese; MUO, metabolically unhealthy obese.

¹Phenotypes based on definition of metabolic syndrome based on the National Cholesterol Education Program (NCEP) Adult Treatment Panel III (ATP III), which includes waist circumference.

Separate and mutually adjusted associations of body mass index and presence of the metabolic syndrome with colorectal cancer, Women’s Health Initiative CVD biomarkers subcohort

Table 2.

BMI (kg/m ²)	Cases (n=474)		Noncases (n = 20,696)		HR ¹	95% CI	HR ²	95% CI	HR ³	95% CI
18.5-<25.0	131	5,033	1.00	Ref.	1.00	Ref.	1.00	Ref.	1.00	Ref.
25.0-<30.0	163	7,504	0.85	0.68–1.07	0.84	0.65–1.09	0.81	0.63–1.06	0.81	0.63–1.06
30.0	180	8,159	0.94	0.75–1.18	0.86	0.66–1.12	0.81	0.61–1.06	0.81	0.61–1.06
<i>p</i> for trend			0.76		0.33		0.18			
MetS										
No	230	10,758	1.00	Ref.	1.00	Ref.	1.00	Ref.	1.00	Ref.
Yes	244	9,938	1.19	0.99–1.44	1.16	0.95–1.41	1.19	0.97–1.47	1.19	0.97–1.47

¹ Age-adjusted HR.

² HRs for waist circumference and MetS are from separate models, adjusted for age (continuous), smoking status (never, former, current), pack-years of smoking (continuous), alcohol intake (drinks/week—continuous), physical activity (MET-hr/week), aspirin intake, dietary calcium intake, dietary folate intake, caloric intake, oral contraceptives (never, ever), hormone therapy (never, ever), parous/multiparous, family history of colorectal cancer in first-degree relative (no, yes), education (less than high school grad, high school grad/some college, college grad, postcollege), ethnicity (white, black, other) and allocation to the OS or specific arm of clinical trials.

³ In addition to the above covariates, waist circumference and MetS are mutually adjusted.

Table 3.

Separate and mutually adjusted associations of waist circumference and presence of the metabolic syndrome with colorectal cancer, Women’s Health Initiative CVD biomarkers subcohort

Waist circumference (cm)	Cases (n = 474)	Noncases (n = 20,028)	HR ¹	95% CI	HR ²	95% CI	HR ³	95% CI
<83.0	154	7,369	1.00	Ref.	1.00	Ref.	1.00	Ref.
83.0–<95.0	151	7,038	1.04	0.83–1.30	1.02	0.79–1.31	1.00	0.77–1.29
95.0	171	6,407	1.39	1.12–1.73	1.34	1.04–1.72	1.29	0.99–1.68
<i>p</i> for trend			0.003		0.05		0.05	
MetS								
No	230	10,758	1.00	Ref.	1.00	Ref.	1.00	Ref.
Yes	244	9,938	1.09	0.90–1.31	1.16	0.95–1.41	1.09	0.88–1.35

¹ Age-adjusted HR.

² HRs for waist circumference and MetS are from separate models, adjusted for age (continuous), smoking status (never, former, current), pack-years of smoking (continuous), alcohol intake (drinks/week—continuous), physical activity (MET-hr/week), aspirin intake, dietary calcium intake, dietary folate intake, caloric intake, oral contraceptives (never, ever), hormone therapy (never, ever), parous/multiparous, family history of colorectal cancer in first-degree relative (no, yes), education (less than high school grad, high school grad/some college, college grad, postcollege), ethnicity (white, black, other) and allocation to the OS or specific arm of clinical trials.

³ In addition to the above covariates, waist circumference and MetS are mutually adjusted.

Metabolic obesity phenotypes defined by presence of the metabolic syndrome¹ and body mass index in relation to risk of colorectal cancer, in the Women’s Health Initiative CVD biomarkers subcohort

Table 4.

Metabolic phenotypes	N cases	N noncases	HR ²	95% CI
Total population (n cases 474; n noncases 20,696)				
MHNW	111	4,491	1.00	Ref.
MUNW	20	542	1.65	0.99–2.74
MHOW	99	5,116	0.80	0.59–1.08
MUOW	64	2,388	1.11	0.79–1.57
MHO	70	3,338	0.85	0.60–1.20
MUO	110	4,821	0.97	0.72–1.32
First 3 years of follow-up excluded (n cases 378; n noncases 20,280)				
MHNW	91	4,404	1.00	Ref.
MUNW	16	518	1.63	0.92–2.89
MHOW	80	5,042	0.79	0.56–1.10
MUOW	51	2,324	1.11	0.76–1.63
MHO	55	3,281	0.85	0.57–1.25
MUO	85	4,711	0.94	0.67–1.33

Abbreviations: MHNW, metabolically healthy normal weight; MUNW, metabolically unhealthy normal weight; MHOW, metabolically healthy overweight; MUOW, metabolically unhealthy overweight; MHO, metabolically healthy obese; MUO, metabolically unhealthy obese.

¹Definition includes waist circumference.

²Adjusted for age (continuous), smoking status (never, former, current), pack-years of smoking (continuous), alcohol intake (drinks/week – continuous), physical activity (MET-hrs/wk), aspirin intake, dietary calcium intake, dietary folate intake, caloric intake, oral contraceptives (never, ever), hormone therapy (never, ever), parous/multiparous, family history of colorectal cancer in first-degree relative (no, yes), education (less than high school grad, high school grad/some college, college grad, post-college), ethnicity (white, black, other), allocation to the OS or specific arm of clinical trials.

Table 5.

Association of quartiles of HOMA-IR and anthropometric measures with colorectal cancer, Women's Health Initiative CVD biomarkers subcohort

	<i>N</i> cases	<i>N</i> noncases	HR ¹	95% CI
HOMA-IR ^{2,3}				
1	125	5,517	1.00	Ref.
2	117	5,436	1.02	0.77–1.34
3	120	5,192	0.84	0.62–1.14
4	93	3,992	0.88	0.63–1.24
<i>p</i> trend			0.39	
Waist circumference				
WC <83.0 cm	145	7,121	1.00	Ref.
WC 83.0–<95.0 cm	143	6,805	1.09	0.84–1.40
WC >95.0 cm	167	6,211	1.52	1.15–2.01
<i>p</i> trend			0.002	

¹ Adjusted for age (continuous), smoking status (never, former, current), pack-years of smoking (continuous), alcohol intake (drinks/week - continuous), physical activity (MET-hr/week), aspirin intake, dietary calcium intake, dietary folate intake, caloric intake, oral contraceptives (never, ever), hormone therapy (never, ever), parous/nulliparous, family history of colorectal cancer in first-degree relative (no, yes), education (less than high school grad, high school grad/some college, college grad, postcollege), ethnicity (white, black, other), allocation to the OS or specific arm of clinical trials and mutually adjusted (HOMA-IR and WC).

² Quartiles: <7.3, 7.3–<11.4, 11.4–<18.7, 18.7.

³ Twenty-one cases and 682 noncases missing HOMA-IR measurement.